Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive February 1, 2011 Jennifer Ringler	Skipping the Needle: Pharm Exec's Brand of the Year Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story
The Motley Fool September 22, 2010 Jordan DiPietro	A Huge Victory for Novartis MS oral drug is approved.
American Journal of Nursing July 2011 Brodkey et al.	Living Well with Multiple Sclerosis Improvements in magnetic resonance imaging and the advent of disease-modifying therapies in the past 15 years have changed the diagnosis and treatment of multiple sclerosis
The Motley Fool December 5, 2007 Brian Orelli	Early Bird Gets the MS Worm Teva's multiple sclerosis drug COPAXONE performs well in a label-expanding trial.
Pharmaceutical Executive November 1, 2005 Alana Klein	Direct to Consumer: A Q&A with Jim Hoyes Multiple sclerosis patients can benefit from a new kind of support system.
The Motley Fool April 11, 2008 Brian Orelli	Teva Tugs at Both Ends of the MS String Teva tries to get multiple sclerosis patients to switch to its drug.
Managed Care January 2008	Too Few Programs to Manage MS? Disease management programs for patients with multiple sclerosis improve outcomes and adherence, reduce disability, and contains cost, but there are not enough of them in existence.
Pharmaceutical Executive November 1, 2008 Jim Wahl	The Mess in MS A five-year forecast of the multiple-sclerosis market following the disruptions of Tysabri.
The Motley Fool September 14, 2006 Brian Lawler	Close Failure for Genzyme Will Genzyme's Campath get approval? Investors shouldn't hold their breath.
The Motley Fool December 7, 2004 Charly Travers	Spin the Medicine Bottle Is a new MS drug going to be a top seller or a bottom-dweller? Here's how to find out. Before investing in any pharmaceutical company with a product in development, go through this exercise to estimate the new drug's potential.
The Motley Fool November 26, 2010 Anders Bylund	Teva Is Running Scared A personal take on the MS medicine market: A little bit of marketing spin keeps the doctor away, but too much makes you a jerk.
The Motley Fool August 27, 2008 Brian Orelli	Teva Tells It Like It Is For Teva Pharmaceuticals, the details only confirmed the great initial report of the clinical trial success for its Parkinson's disease treatment Azilect.
BusinessWeek December 30, 2009 Kerry Capell	Multiple Sclerosis: A Breakthrough Is on the Way A number of improved treatments will be available soon, and Novartis' Fingolimod could lead the way
The Motley Fool March 14, 2008 Brian Orelli	ALS: The Disease That Kills Drugs Teva's Copaxone doesn't help patients with Lou Gehrig's disease. Investors, take note.
American Family Physician November 15, 2004 Peter A. Calabresi	Diagnosis and Management of Multiple Sclerosis The diagnosis of multiple sclerosis should be made by a physician with experience in identifying the disease. Five disease-modifying treatments for multiple sclerosis have been approved by the U.S. Food and Drug Administration.
Pharmaceutical Executive August 1, 2008 George Koroneos	Hard of (Ad)hering Companies have responded to declining profits with a proliferation of patient compliance programs. But where is pharma in this paradigm shift?
Pharmaceutical Executive August 1, 2011 Jennifer Ringler	The Adherence Fight: A TKO? Why does the match against medicines compliance always seem to end in an easy knockout?
American Journal of Nursing October 2005 Charlotte Thomas-Hawkins	Self-Management of Chronic Kidney Disease Effective management of this disease requires the patient to be the principal illness manager and this skill requires the nurses guidance and support.
Pharmaceutical Executive September 1, 2008 Jeffrey S. Aronin	The Orphan Opportunity The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains
The Motley Fool May 26, 2010 Brian Orelli	Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming.
Pharmaceutical Executive December 1, 2011 William Looney	The Medicines Adherence Challenge Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma, but is it? An expert round table examines how best to make progress and agree on some practical steps for incorporation in the campaign agenda.
The Motley Fool June 30, 2005 Brian Gorman	Teva's Non-Generic Side The drug company is working hard to cement its position in the market for multiple sclerosis meds. Investors, take note.
The Motley Fool October 1, 2009 Anders Bylund	Why I'm Invested in Tysabri and Elan This Motley Fool analyst has investigated Elan both as an investor and a patient. What's his verdict on the company?
Pharmaceutical Executive November 1, 2012 Lauri Mitchell	Who Pays for Specialty Medicines? Providers and patients fish for that delicate balance between access and abandonment.
Pharmaceutical Executive April 1, 2012	Ad Stars The campaigns chosen as this year's Pharm Exec Ad Stars include a diverse mix of clients, health conditions, and media channels.
BusinessWeek March 14, 2005 Arnst & Barrett	Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments
Pharmaceutical Executive January 1, 2006 Gina Ashe	Alternative Media: Patient Bloggers on Your Brands Find out what patient bloggers are saying about your pharmaceutical brands.
Pharmaceutical Executive January 1, 2009 Amit Agarwal	Overlooked Opportunities For pharma companies facing a difficult economic climate, pairing diagnostics with therapies offers a powerful incentive: Manufacturers can improve sales by helping physicians find the most appropriate therapeutic option.
Pharmaceutical Executive June 1, 2014 Ben Comer	Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy.
BusinessWeek June 12, 2006 Michael Arndt	Big Pharma's Nurse Will See You Now Drug companies are hiring RNs to educate patients - and boost marketing.
Pharmaceutical Executive October 1, 2011	Patient Advocacy: The Last 30 Years The rise of advocacy groups has helped patients find their voice, but the power to change health profiles remains an elusive goal.
Managed Care August 2004 Alan Lotvin	Specialty Pharmacy Presents Unique Set of Challenges Only a small percent of a typical health plan's population takes medicine for conditions outside the generalist's scope. But it's a big portion of the drug bill.
The Motley Fool July 8, 2008 Brian Orelli	Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note.
Pharmaceutical Executive January 1, 2013 Al Topin	The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author.
Pharmaceutical Executive December 1, 2006 Marcee Nelson	Direct to Consumer: Don't Wait By stocking waiting rooms with educational drug information, pharma can help get doctor-patient communication off on the right foot.
BusinessWeek March 10, 2011 Kanoko Matsuyama	From Soup to MS Drug: One Fungus's Journey Gilenya, Mitsubishi Tanabe's parasite-derived pill for multiple sclerosis, could be a blockbuster.
Pharmaceutical Executive January 1, 2006 Maggie Helmig	Direct to Consumer: Patient Education Reform Marketers can empower patients to start a dialogue with their doctors.
Pharmaceutical Executive February 1, 2014 Ben Comer	The Active Patient: Faces Of Change Advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy all fueled by the hour-to-hour passion of living with a disease and having access to social media.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Multiple Sclerosis: The Advent of the Orals The $8 billion dollar multiple sclerosis market is set to double the number of available treatments in the near future, with a dramatic switch from injectables to oral medications.
The Motley Fool March 26, 2009 Brian Orelli	R&D Your Way to Higher Sales Biogen is trying to lower side effects to increase sales.
American Journal of Nursing January 2008 Maslow & Mezey	Recognition of Dementia in Hospitalized Older Adults Recognition of Dementia in Hospitalized Older Adults proposes several approaches that hospital nurses can use to increase recognition of dementia. This article describes the Try This approaches, how to implement them, and how to incorporate them into a hospital's current admission procedures.
American Family Physician November 15, 2005 Haas et al.	Management of the Difficult Patient All physicians must care for some patients who are perceived as difficult because of behavioral or emotional aspects that affect their care. Specific communication techniques and greater patient involvement in the process of care may enhance the relationship.
The Motley Fool October 18, 2007 Brian Lawler	Genzyme Shows Off a Drug Candidate A top compound in development could become an important MS treatment.
Managed Care December 2003 Martin Sipkoff	Health Plans Begin To Address Chronic Care Management As with so much else in health care, observing protocols, analyzing data, and rethinking benefit designs are important.
Pharmaceutical Executive June 1, 2005 Michael Parisi	Direct to Consumer: Patient-Reported Outcomes New clinical endpoints mean exacting messages for patients. Physicians and other healthcare professionals can use these tools now as they attempt to evaluate the effectiveness of treatments and optimize drug utilizations to combat the high cost of drug treatment.
The Motley Fool March 1, 2006 Bill Mann	Tysabri: As Bad as AIDS? A report on the Elan/Biogen drug gets blown out of proportion on the eve of an FDA review. To say that a lot rides on the outcome of this meeting for Elan shareholders is an understatement.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
Nursing June 2011 Daniel A. Hussar	New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis.
Pharmaceutical Executive December 1, 2011 Ben Comer	Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
Pharmaceutical Executive March 1, 2006 Alana Klein	Direct to Consumer: Q&A with Jill Balderson More Education, Less Promotion. Patient materials should teach rather than tell.